Transcatheter Aortic Valve Replacement: Team Construction and Operation Specifications Recommended by Chinese Experts
Junbo Ge
DOI: https://doi.org/10.4103/cp.cp_29_18
2018-01-01
Cardiology Plus
Abstract:Introduction Transcatheter aortic valve replacement (TAVR) refers to the replacement of an aortic valve by placing an assembled aortic valve into a diseased aortic valve through a catheter. TAVR is a revolutionary technique for the treatment of aortic valve stenosis. Currently, European and American guidelines recommend patients with high or moderate risk of aortic stenosis for TAVR.[1-3] TAVR is a complex, high-risk technology, which requires the cooperation of many disciplines, such as departments of cardiology, cardiac surgery, imaging, and anesthesiology, so it is necessary to establish a multidisciplinary heart team. The domestic TAVR was approved for sale in China in May 2017, and TAVR will be widely promoted in China. In order to promote the standardization, safety, and smooth promotion of TAVR in China, this proposal was organized by the structural cardiology group of the Chinese Medical Doctor Association Department of cardiovascular physicians, the Chinese Medical Doctor Association, the Chinese Medical Association for cardiovascular diseases, and the structural cardiology group. This recommendation is primarily written for TAVR via the peripheral vascular pathways. Background TAVR is becoming a more secure and mature technology. Recently, TAVR has been performed with a “minimalist approach,”[4,5] and the recognition of the TAVR team is gradually weakening. However, under current medical guidelines in China, it is still necessary to prioritize the implementation of a TAVR team for several reasons. First, although TAVR is growing into a safe and standard procedure, it is still a high-risk and complex surgery compared to traditional interventional procedures. Even in the latest clinical trials, the perioperative mortality of TAVR is still 2%-4%, and the incidence of permanent pacemaker implantation, paravalvular leak, and vascular complications is still relatively high.[6,7] Second, the domestic valve currently listed in China is the first-generation valve, which does not have the function of recycling, relocating, and preventing leakage. There is a high proportion of two-leaf valves and serious calcification in Chinese TAVR patients.[8,9] Therefore, there is a high risk in performing TAVR in China at present. Third, TAVR is a complex technology, its classical development methods require coordination among multidisciplinary personnel such as cardiology, cardiac surgery, imaging, and anesthesiology.[10] Finally, TAVR has an steep learning curve,[11] and TAVR is more successful when conducting system-based training and team-standardized operations. In order to promote the standardization, safety, and smooth promotion of TAVR in China, it is suggested that the multidisciplinary heart team (MDHT) of TAVR should be established in China to train the team personnel systematically and to promote adherence to the corresponding technical specifications. Team composition and personnel requirements Referring to the international guide,[12] it is recommended that the MDHT of TAVR consists of interventional physicians, cardiovascular surgeons (cardiologists), echocardiogram physicians, radiologists, anesthesiologists, nurses, and related professional and technical personnel, and the team must undergo systematic training. TAVR team members are required to include the following:[13] Interventional physicians: The TAVR interventional physicians are the core of the MDHT team. They should comprise 3-4 members, have managerial experience, hold the title of deputy chief physician, and all members should have experience in interventional therapy for cardiovascular disease. They are the main decision makers of the preoperative assessment, the operators of the TAVR surgery, and responsible for postoperative follow-up. The lead interventional physician should handle more than 200 cases per year and have received systematic training. Other assistant doctors should have the qualifications of an attending physician or above and have experience in independent intervention. The lead interventional physician should be able to independently analyze the patient's imaging data, especially the multiple-slice spiral computed tomography (MSCT), to determine whether the patient is suitable for the operation and to select the approach and valve model. The first twenty cases of TAVR should be completed under the guidance of experienced surgeons, and then TAVR may be carried out independently Cardiac surgeon: A cardiac surgeon, who is the deputy director of the doctor, is required to perform more than fifty cases of heart valve surgery in 1 year before they are suitable for a TAVR team Radiologist: A senior doctor who is above the title senior of doctor, familiar with MSCT, and has completed the scanning and analysis of MSCT Anesthesiologists: An anesthesiologist with at least 3 years of experience in cardiovascular anesthesia and at least one assistant who has completed TAVR anesthesia Echocardiographer: One echocardiographer with >5 years of experience in echocardiographic work, >1 year experience in transesophageal echocardiography, and at least one assistant to complete the preoperative, intraoperative, and postoperative echocardiographic examinations of TAVR Nursing staff: The nursing team members are generally served by specialist nurses, who are divided into ward specialist nurses, catheter room nurses, and coronary care unit (CCU) nurses. At least one nurse should have >3 years of working experience Others: The center for TAVR must have a cardiac surgeon with the ability to deal with vascular complications. If necessary, the intensive care unit (ICU), respiratory department, and geriatrics should be involved. Team responsibilities Preoperative screening and evaluation is completed by the MDHT, including the following: (a) The intervention physicians evaluate the preoperative condition of the patients as a whole, assess whether a TAVR is needed, whether they could benefit from the operation, and whether their anatomy is suitable for TAVR. (b) The cardiac surgeons assess the risk of cardiac surgery and whether a surgical assistance approach is needed, the approach is appropriate, and make a remedial surgical plan available. (c) The echocardiographer evaluates cardiac function, valve conditions, and aortic root anatomy. (d) The radiologist assesses whether the patient's anatomy is suitable for TAVR and coronary artery lesions. (e) The anesthesiologists assess the risk of anesthesia for surgery. It is recommended that members of the TAVR team members determine whether the patient is suitable for TAVR through open discussion Intraoperative Collaboration: During the operation, the team members must be at the scene, perform their duties, and work closely together. The intervention physicians are responsible for the operation, and other relevant personnel of the various departments should be well coordinated. For example, the nurse prepares the apparatus, the anesthesiologist performs and closely monitors anesthesia, and the echocardiographer performs ultrasound monitoring if necessary. The radiologist should adjust the digital subtraction angiography and assist the angiography. Professionally trained personnel loads the valve and the cardiac surgeon assists in the treatment of the approach and can perform the operation at any time Perioperative management: In anticipation of the patient's possible postoperative complications and hemodynamic abnormalities, it is recommended that the patient be managed by a trained specialist after the operation. Intensive care can be carried out in CCU or ICU or specialized TAVR ward units, and the ward should be closely monitored and managed by the ward's competent physician and nurse. Surgeons should explain the relevant precautions. For particularly critical patients, it is necessary to maintain an increased frequency of observation until the patient's condition is stable. The anesthesiologist should perform a postoperative inspection. If the patient's perioperative condition changes or complications occur during this period, either the doctors in charge of the ward or a surgeon should organize corresponding experts to formulate a rescue strategy for rescue Postoperative follow-up: The interventional physician is primarily responsible for the postoperative follow-up, while the radiologist and echocardiographer assist in completing the relevant examinations Summary and improvement: Team members should regularly organize discussions and summarize the experience of completing cases and continuously improve technical points, implementation plans, and operation processes. Team specifications Interventional physician Preoperative assessment and screening: This includes clinical factors and imaging evaluation. Clinical assessment includes: (a) whether valve replacement is required; (b) surgical risk assessment;[13] (c) TAVR contraindications. Imaging evaluation is mainly to assess whether the patient's anatomy is suitable for TAVR. It is recommended that the head physician analyze the imaging data of the patient (MSCT) to determine whether the patient is suitable for surgery and to select a valve model Intraoperative: The interventional physician is the main operator of TAVR, and the main points of operation refer to the “Chinese expert consensus on Transcatheter Aortic Valve Replacement”[13] Perioperative management: Patients may be managed by the CCU or other nonsurgeons after surgery, but the interventional physician still needs to play a major role in postoperative management. The relevant doctors should be informed of the surgical situation, complications, and precautions, and relevant treatment strategies should be formulated. Patients should be visited frequently, especially in critical cases. If conditions permit, it is recommended to set up postoperative TAVR ward to manage patients after the surgery Postoperative follow-up: It is recommended that doctors follow up with the patients at 1, 3, 6, and 12 months after the operation, and once a year routinely thereafter. The follow-up contents include the position and function of the prosthetic valve, the heart function, and the complications. The examination items mainly include echocardiography, electrocardiogram (ECG), and other items including brain natriuretic peptide, and blood routine. Cardiac surgeon Preoperative assessment and screening: Assessment should be made according to the Society of Thoracic Surgeons scoring system, the European System for Cardiac Operative Risk Evaluation score, Weakness Index, the possibility of major organ damage that cannot be improved by surgery, related surgical operation disorders, etc.[2] These factors should be combined with the operation experience of the cardiac center and comprehensively evaluate the surgical risk of patients. When a surgical approach is required, assess the feasibility and safety of the associated approach Intraoperative collaboration and postoperative management: Assist in the treatment of related approaches. For emergent surgical operations, remedial surgery is performed after detailed discussion with the interventional physician. Radiologists Imaging evaluation by radiologists is the focus of preoperative assessment and screening of TAVR, of which MSCT is particularly important. MSCT scan technique requires:[14] (i) recommended thickness: ≤1 mm; (ii) ECG gating, taking the end of systolic period (about 40% of the cardiac cycle); (iii) an enhanced computed tomography (CT) scan (injection contrast); (iv) imaging the body from below the neck down to the knee joint, to assess all available peripheral vascular access (femoral artery, subosseous artery, etc.). For patients with aortic stenosis, β-blockers and nitrates should be avoided to prevent hemodynamic complications during examination Aortic root scanning must be done with ECG gating techniques (retrospective or prospective) and a high-pitch scan. The abdominal aorta and iliac femoral artery do not require ECG gating and high-pitch scanning, which can significantly reduce the radiation dose and the dosage of contrast medium MSCT analysis includes:[14] (i) the circumference, area, and diameter of aortic annulus as the main reference for TAVR valve selection; (ii) aortic root anatomy, including coronary artery height, aortic sinus width, ascending aorta width, sinus tube junction, and left ventricular outflow tract; (iii) aortic valve morphology, judged to be two leaf or three lobed, analysis of leaflet thickness, fusion, and calcification (including calcification, distribution, and continuity). The leaflet morphology can also serve as a reference for selection of TAVR valves. (iv) assessment of the vascular approach, including the femoral artery, subclavian artery, carotid artery, ascending aorta, and transapical approach to understand the internal diameter, distortion, and calcification of the approach; (v) coronary artery lesions; (vi) MSCT assists in determining the best angiographic angle of the operation. In addition, intraoperative radiologists should assist in the adjustment of the patient's head for digital subtraction angiography and completing the angiography. Anesthesiologist The anesthesiologist is responsible for: Preoperative assessment: The anesthesiologist should check the patient before the operation. By reviewing the patient's medical history, physical examination, laboratory examination, and imaging results, they can comprehensively understand the general situation of the patient, the history of noncardiac disease, and cognitive ability to assess the anesthesia risk. They should ask about medication history and allergy history and make a routine airway assessment. Preoperative medication can help patients to relieve anxiety before induction of anesthesia and also help avoid adverse cardiac events due to tachycardia Intraoperative collaboration: For patients with TAVR, anesthesiologists should open at least one unobstructed venous access (recommended central venous catheter) and monitor invasive blood pressure. The necessary monitoring items during the operation include ECG, finger oxygen saturation, body temperature, end-tidal carbon dioxide partial pressure, central venous pressure, and active clotting timeIn order to correct any possible arrhythmia, the electrode sheets of external cardioversion should be placed and connected before anesthesia induction. At the beginning of the TAVR operation, general anesthesia (single-lumen endotracheal intubation) is generally recommended. Anesthesia induction should be slow and stable, and the sinus rhythm should be maintained as far as possible during anesthesia managementBe careful to maintain adequate preload and avoid using vasodilator drugs to ensure ventricular filling pressure. Norepinephrine or phenylephrine can be used in small doses to maintain systemic resistance, avoid hypotension, and ensure adequate perfusion of the hypertrophic myocardium. To prevent tachycardia, anesthesiologists will also need to avoid severe bradycardia. Possible intravenous anesthetics are etomidate, propofol, ketamine, and opioids such as fentanyl, sufentanil, remifentanil (small dose of intravenous infusion), and possible inhaled anesthetics are sevoflurane, desflurane, muscle relaxants such as rocuronium, and cisatracurium. On the one hand, it is considered that patients with TAVR are generally older. On the other hand, if the tracheal catheter is removed after surgery, benzodiazepines are not recommended. If inhalation anesthetics are selected, attention should be given to controlling the concentration of drug inhalation and avoiding excessive inhibition of myocardiumIn an experienced TAVR center, the operation can also be performed with a local anesthesia combined with sedation. Local anesthetic sedative prohibition is used in the following situations: severe sleep apnea, predicting poor airway, patients cannot be supine, severe gastroesophageal reflux, mental disorders or communication disorders, or the transesophageal echocardiography must be used during surgery. The sedative drug generally chosen is dexmedetomidine for continuous intravenous infusion. Small doses of opioids can be added to the femoral artery sheath. Before the balloon dilation, propofol is given as needed, with no inhibition of breathing as a criterion. During the operation, the bispectral index can be monitored and maintained at 65-75. The patient's respiratory and circulatory conditions must be closely monitored throughout the procedure and general anesthesia must be prepared as a standby. If there are complications, change to general anesthesia immediately. If a patient has an upper respiratory tract obstruction such as a tongue falling, try to wake up or open the oropharyngeal airway. If the chest wall stiffness or pulse oxygen saturation noticeably drops, try mask ventilation. If there is no noticeable improvement, the operation should be immediately switched to using general anesthesiaPostoperative monitoring: If the operation is performed under general anesthesia, early extubation is recommended. It is suggested that patients be sent to the ICU for postoperative care, monitoring and recording patient's postoperative recovery, including vital signs, cognitive function, volume, and bleeding. The recovery of cardiac function should be evaluated continuously, the healing of the surgical incision is closely observed, and the formation of hemorrhage, hematoma, pseudoaneurysm, and thromboembolism should be caught quickly. Proper individualized analgesia can help patients recover more quickly. Echocardiographer Preoperative assessment: To determine whether the aortic valve is severely stenotic: Measuring the left ventricular outflow tract diameter, the peak and mean pressure difference across the aortic valve is measured by continuous Doppler and the left ventricular outflow tract is measured by pulsed Doppler. Flow time integration, the aortic valve area is calculated according to the continuity equation methodThe anatomical structure of the left ventricular outflow tract, aortic ring, aortic root, the junction of the trunk of the sinus, the ascending aorta, and the aortic valve are evaluated for TAVR. The patient's valvular condition, left ventricular function, pulmonary hypertension, and pericardial effusion are assessed. For patients with partial left ventricular dysfunction, perform the dobutamine test if the peak value and mean pressure difference across the aortic valves do not reach the severe standardIntraoperative assessment: (i) Evaluating the degree of reflux of the aortic valve and stenosis of the aortic valve after balloon dilation; (ii) The position of artificial aortic valve should be checked immediately after implantation of artificial aortic valve and its function evaluated, including valve reflux and paravalvular leakage, mean pressure difference of artificial aortic valve, and valvular area. (iii) Rapid monitoring of various complications: Determine the cardiac tamponade caused by the guidewire penetrating the left and right ventricles, left ventricular failure, or severe primary arterial regurgitation; a possible cause of sudden increase in mitral regurgitation during surgery, especially the guidewire wrapped around the mitral chordae Postoperative follow-up: Evaluation of the area of artificial aortic valve flap; accurate quantitative artificial aortic valve reflux and measurement of paravalvular leakage; evaluation of other valve conditions and the size and function of the heart. Nursing staff Preoperative evaluation and nursing: Complete routine tests, blood grouping, blood preparation, and related examinations according to doctor's advice before surgery. The purpose, method, and precautions of the operation should be presented to the patient to relieve nervousness and achieve cooperation. Prepare the skin on the day of the operation. Follow strict fasting and water ban. Follow the doctor's advice to catheterize and establish a venous access. Preoperative medication should be given according to the anesthesiologist, and the patient should be closely observed for adverse reactions. The nurses in the catheter room should prepare the TAVR instruments before operation Intraoperative collaboration: During the operation: Prepare the operating table, assist with disinfection, tissue, and catheterization, attach the electrodes and defibrillation patches, connect the hemodynamic and ECG monitoring equipment, and dismantle the relevant surgical instruments. Check the instruments 1 day before operation to improve the accuracy of the instruments Postoperative care: There should be a comprehensive understanding of the patient's surgical situation and any abnormalities during the operation, cooperate with the doctor for the appropriate treatment. Postoperative general anesthesia care: Closely monitor the patient's vital signs, consciousness, and blood oxygen saturation until they are stable and recorded. Observe ECG, basic physiological reflex, and perception of patients. Follow the doctor's advice to fast, ban water for 2-4 h, then start a small amount of liquid diet, no cough, and give a semi-liquid diet. Observe the wound condition, skin temperature, skin color, and arterial pulse condition. Follow the doctor's instructions to brake the lower limbs and move the toe to prevent thrombosis. Do the related catheter care: Endotracheal intubation, temporary pacemaker, deep venous catheter, catheter, and invasive arterial blood pressure catheter. Observe whether there are the following complications: arrhythmia, cerebral infarction, puncture-site bleeding, paravalvular leakage, cardiac tamponade, or myocardial infarction. Patients should be encouraged to get out of bed early to prevent thrombosis. Other personnel Other personnel include cardiac surgeons who can deal with vascular complications and others such as neurology, respiratory physician, and geriatric staff. These personnel must be fixed, trained to familiarize with, or understand the clinical problems related to TAVR. Although these people are not necessary for a regular TAVR team, they can work together with the TAVR team to deal with related issues when required, such as preoperative assessment and complication handling. Note: This article is published in the Chinese Journal of interventional cardiology in Chinese simultaneously. Members of the writing group Daxin Zhou (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Wenzhi Pan (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Kefang Guo (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Cuizhen Pan (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Xue Yang (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Yongjian Wu (Fuwai Hospital, Beijing); Xiangqing Kong (The First Affiliated Hospital of Nanjing Medical University, Nanjing); Xianying Liu (The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou); Junbo Ge (Zhongshan Hospital Affiliated to Fudan University, Shanghai) Panelists (in alphabetical order by surname) Bo Yu (The Second Affiliated Hospital of Harbin Medical University, Harbin); Cuizhen Pan (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Daxin Zhou (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Gejun Zhang (Fuwai Hospital, Beijing); Guangwei Wu (The Guangxi Zhuang Autonomous Region People's Hospital, Nanning); Guangyi Wang (PLA General Hospital, Beijing); Guangyuan Song (Fuwai Hospital, Beijing); Jianan Wang (The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou); Jianfang Luo (Guangdong Provincial People's Hospital, Guangzhou); Junbo Ge (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Kefang Guo (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Lihua Guan (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Mao Chen (West China Hospital of Sichuan University, Chengdu); Rong Yang (The First Affiliated Hospital of Nanjing Medical University, Nanjing); Shiliang Jiang (Fuwai Hospital, Beijing); Weifeng Wu (The First Affiliated Hospital of Guangxi Medical University, Nanning); Weihua Zhang (Yan'an Hospital, Kunming); Wei Ma (Peking University First Hospital, Beijing); Wenzhi Pan (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Xiangqing Kong (The First Affiliated Hospital of Nanjing Medical University, Nanjing); Xianxian Zhao (Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai); Xianyang Zhu (General Hospital of Shenyang Military Region, Shenyang); Xianying Liu (The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou); Xue Yang (Zhongshan Hospital Affiliated to Fudan University, Shanghai); Yong Huo (Peking University First Hospital, Beijing); Yongjian Wu (Fuwai Hospital, Beijing); Yong Sun (The Second Affiliated Hospital of Harbin Medical University, Harbin); Yongwen Qin (Changhai Hospital of Second Military Medical University of Chinese PLA, Shanghai); Yuan Feng (West China Hospital of Sichuan University, Chengdu); Yushun Zhang (The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an); Zhiyuan Song (Southwest Hospital of Third Military Medical University, Chongqing); Zhi Zeng (West China Hospital of Sichuan University, Chengdu); Zhiwei Zhang (Guangdong Provincial People's Hospital, Guangzhou); Zhongying Xu (Fuwai Hospital, Beijing) Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
What problem does this paper attempt to address?
-
Heart team construction and operation in transcatheter aortic valve replacement
Yong HUO,Wei MA
DOI: https://doi.org/10.7507/1002-0179.201801011
2018-01-01
Abstract:Transcatheter aortic valve replacement (TAVR) has been a crucial treatment for elder patients with aortic stenosis in developed countries,which is still at its beginning in China.TAVR is a risky and complicated technic;and to promise the long-term development of it,we need to build a multiple disciplinary heart team consisted of doctors from different specialties and guided by various disciplines,also to guarantee the team operates well.In order to help Chinese doctors understand heart team well,this article describes component parts and requirement for each member of the team,in aspect of cardiologist,cardiac surgeon,echocardiologist,radiologist,anesthesiologist and nursing team;and discuss team operation mechanism through pre-procedural evaluation,procedural cooperation,peri-procedural management and post-procedural follow-up.
-
Experience in Treating a Case of the Cardiac Rupture During Transcatheter Aortic Valve Implantation Procedure
Wei-Min Zhang,Jian-Mao Hong,Fan He,Guo-Sheng Fu,Fei-Cheng Yu
DOI: https://doi.org/10.1097/cm9.0000000000001098
IF: 6.133
2020-01-01
Chinese Medical Journal
Abstract:To the Editor: A 70-year-old male patient underwent transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. Echocardiography showed that the peak velocity in aortic valve was 4.33 m/s, with a peak pressure gradient of 75 mmHg and a mean pressure gradient of 38 mmHg. The end-systolic dimension and end-diastolic dimension of left ventricle was 31.7 and 50.0 mm, respectively. The internal diameter of aortic annular was 30.7 mm, and the diameter of aortic sinus was 37.3 mm. The area of valve was 0.87 cm2. The computerized tomography indicated a bicuspid aortic valve of 27.3 mm diameter according to 85.6 mm perimeter of aortic annulus, or an aortic valve of 27.4 mm diameter according to 569 mm2 valve orifice area. A 26 mm Venus-A valve (Venus Medtech, Hangzhou, China) was implanted. When we used a 20Fr balloon to dilate the aortic valve, the patient's systolic blood pressure dropped to 70 mmHg in 5 min. The transesophageal echocardiography (TEE) showed a rapidly increasing pericardial effusion. A single-chamber central venous catheter was inserted immediately into the pericardial cavity through the left fourth intercostal space. Five hundred milliliter bright red bloody hemopericardium was drawn out quickly and infused back into the body through the left femoral artery. The patient's blood pressure recovered after the intervention, but the pericardial effusion was not improved as monitored by TEE. We decided to send the artificial valve to the predetermined location and released it immediately under fluoroscopy. Simultaneously, the bloody hemopericardium was continuously pumped back into the patient's femoral artery. Slight perivalvular leak was detected by the fluoroscopy and TEE. Because we observed that the hemopericardium was with bright red blood rather than blue-black color, there was a high possibility of the left ventricle rupture. Indeed, the Color Flow Doppler imaging clearly showed that a bundle of blood from the left ventricle ejected to the pericardial cavity [Figure 1A]. We then performed an urgent thoracotomy through the median sternal incision. On the left ventricular surface, we found a 1 cm gap, which was 8 mm away from the left anterior descending branch and parallel with the ventricular septum. Blood ejected to the outside of the left ventricle from the gap with every heartbeat [Figure 1B]. We used two interrupted horizontal mattress sutures with 2-0 Prolene on two felts to close the cleft. There was no myocardial infarction, no stroke, no incision infection, or conduction block post-operatively. The patient was discharged 9 days later.Figure 1: (A) The Color Flow Doppler imaging showed a bundle of blood from the left ventricle ejected to the pericardial cavity. (B) On the left ventricular surface, we found a 1 cm gap, which was 8 mm away from the left anterior descending branch (LAD) and parallel with the ventricular septum. Blood ejected to outside of the left ventricle from the gap with every heartbeat. LV: Left ventricle; RVOT: Right ventricular outflow tract.Some cardiologists suggest that the TAVI procedure can be extremely simplified by finishing the procedure unilaterally in the catheter lab without cardiac surgeons’ assistance. However, the case in this study strongly suggests that to ensure patients’ safety, the TAVI procedure must be performed by an integrated heart team including both physicians and surgeons in the hybrid theater with cardiopulmonary bypass instruments standing by.[1] The TAVI procedure calls for physicians’ experience in interventional technique, as well as surgeons’ knowledge of cardiac anatomy and quick response to severe surgical complications. Furthermore, anesthetists and perfusionists are better coordinated by the dual effort of physicians and cardiac surgeons, adding an extra layer of comprehensive safety for patients. The combination of internal and surgical technology has become essentially required in training programs for cardiac surgeons in some Chinese heart centers. The disinfection and draping of TAVI should be carried out according to the surgical requirements before the surgery. To minimize the time of disinfection, patient's chest should be fully exposed for urgent thoracotomy if needed. We recommend that at least one cardiac surgeon should participate in the operation. Main complications of TAVI include A-V block, stroke, perivalvular leaking, and cardiac rupture, which are the most life-threatening.[2] High quality performance in each step of the TAVI procedure is the key to prevent heart rupture. Early diagnosis and in-time treatment of the heart rupture can substantially reduce the mortality and disability. Calcified aortic annulus, fragile and scarred myocardium due to likely co-existence of ischemic heart disease with previous infarcts can be the predisposing factors for the development of tamponade during TAVI. Common causes of cardiac tear include the damage of the left ventricle by the stiff guide wire, and the rupture of the aortic annular during the valve dilation by the balloon.[2,3] The most frequently heart injured site is the anterior wall of the left ventricle about 2 cm left lateral to the left anterior descending artery distribution.[4] A strong sign of heart rupture is massive continuous pericardial effusion detected by TEE. Consequently, both blood pressure and pulse pressure drop. Therefore, TEE and blood pressure monitoring are critical for diagnosis of cardiac rupture. While reviewing the video recorded TAVI procedure, we found that the stiff guide wire caused the cardiac rupture in our case. When we were dilating the aortic valve with the balloon, the pump flow of the heart did not reduce as expected due to rapid heart pacing. Moreover, the dilated balloon slipped to the left ventricle transiently, which pushed the stiff guide wire to cut the myocardium. Finally, the stiff guide wire broke the left ventricle along the interventricular septum. Stiff wire provides excellent support for the delivery of the valve and is an important component of TAVI procedure. But it also has the potential to cause significant trauma to the left ventricle myocardium. The operators sometimes may focus exclusively on the area of valve dilation or valve deployment. This might briefly divert the attention from the stiff wire in the left ventricle that could migrate and cause the catastrophe. Hence, great caution is necessary during the introduction of the stiff wire in the left ventricle.[5] From anatomic and pathophysiological points of view, it would be reasonable to be concerned when a patient has a small cavity and a hypercontractile thin ventricle, where the aorto-mitral angle is narrow. Thereby, for elderly female patients with these risk factors, more attention is needed to be payed to prevent cardiac rupture.[4] To rescue patients from potential heart rupture during TAVI procedure, pericardiocentesis should be performed quickly to release the cardiac tamponade.[5] A three-way plug valve and a transfusion tube can be used to connect the pericardial drainage tube and the femoral artery sheath. Thus, the blood in the pericardium can be pumped out and infused back to the body through the femoral artery immediately and readily. Surgical intervention should be performed as early as possible.[2,5] It is worth noting that long-time poor perfusion will cause multiple organs failure, including the heart, the brain, and the kidney. In addition, cautions should be taken to avoid a secondary coronary artery injure during the repair of the heart rupture. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the article. The patient understands that his name and initials will not be published and due efforts will be made to conceal the identity of the patient, although anonymity cannot be guaranteed. Conflicts of interest None.
-
Clinical practice and prognosis of emergent transcatheter aortic valve replacement
周道,刘先宝,范嘉祺,王力涵,胡泼,蒋巨波,蒲朝霞,林心平,李华俊,戴晗怡,朱钢杰,许烨铭,王建安
DOI: https://doi.org/10.3760/cma.j.issn.1671-0282.2022.03.019
2022-01-01
Abstract:Objective:To evaluate the effectiveness and prognosis of emergent transcatheter aortic valve replacement (TAVR) and to provide standardized procedural suggestion for the development of emergent TAVR in China.Methods:From January 2020 to April 2021, 12 patients who underwent emergent or salvage TAVR in the Second Affiliated Hospital Zhejiang University School of Medicine were retrospectively enrolled from the TORCH registry (Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population, a prospective cohort study; NCT02803294). Baseline, periprocedural and 30-day follow up data were collected. Post-operative data were compared with pre-operative data using Paired-Samples test.Results:Patients’ median Society of Thoracic Surgeons score (STS score) was 15.432%. There was a significant decrease of mean gradient after emergent TAVR procedure (1.69 m/s
vs. 4.90 m/s,
P<0.01). During the 30-day follow up, there were 1 patient (8.3%) died and 2 patients received permanent pacemaker implantation. No disabling stroke, acute kidney injury, major vascular complication occurred during the first month after emergent TAVR. Among the survival patients, there was a significant releasing of heart failure symptoms to New York Heart Association function stage Ⅰ/Ⅱ in 81.8% patients at 30-day follow up. Left ventricular ejection fraction also improved significantly from (47.4±9.5)% to 58.8±8.0% (
P= 0.026). The mean gradient were (1.57±0.30) cm
2 and no patients had a moderate or severe paravalvular leakage. Besides, a significant decrease of pro-B-type natriuretic peptide (1 089.9 pg/mL
vs. 12 215.5 pg/mL
, P=0.001) and troponin T (0.020 ng/mL
vs. 0.337 ng/mL,
P=0.003) were found at 30 days after emergent TAVR.
Conclusions:For patients with severe aortic stenosis and acute cardiac decompensated, emergent TAVR is a safe and effective rescue treatment.
-
[Chinese guideline for the clincal application of transcatheter aortic valve replacement]
National Center for Cardiovascular Diseases,National Center for Quality Control of Structural Heart Disease Intervention,Chinese Society of Cardiology,Chinese Society for Thoracic and Cardiovascular Surgery,Joint Expert Group on TAVR Guidelines
DOI: https://doi.org/10.3760/cma.j.cn112137-20221106-02332
2023-03-28
Abstract:Transcatheter aortic valve replacement (TAVR), as an important procedure for aortic valve diseases worldwide, features with a late start and rapid development in China. In the process of clinical application, the lack of standard guidelines and training system has brought challenges to the widespread use of this technique. In order to standardize the application of TAVR technique and improve the quality of medical care, the National Center for Cardiovascular Diseases and the National Center for Quality Control of Structural Heart Disease Intervention, together with the Chinese Society of Cardiology and the Chinese Society for Thoracic and Cardiovascular Surgery, jointly established an expert group on the guidelines for TAVR, combined with the recommendations of international guidelines and the current clinical practice in China, integrated the latest evidence in China and worldwide to develop the clinical guideline of TAVR with extensive consultation (Chinese Expert Consensus). The guideline mainly included 11 parts: methods, epidemiological feature, TAVR devices, requirements of cardiac teams, recommendations for TAVR indications, perioperative multimodality imaging evaluation, surgical procedures, anti-thrombotic strategies after TAVR, prevention and treatment of complications, postoperative rehabilitation and follow-up, limitations and prospects, aiming to provide reasonable recommendations for all-level clinicians in China.
-
Clinical study of anesthesia management and treatment strategies for emergency transcatheter aortic valve replacement
He Wei,Liu Yi,Liu Xianbao,Kong Minjian,Lin Xinping,Ding Minjun,Cheng Jifang,Yan Min
DOI: https://doi.org/10.3760/cma.j.issn.1671-0282.2022.07.018
2022-01-01
Abstract:Objective:To discuss the essentials of anesthesia management and treatment strategies for emergency transcatheter aortic valve replacement (TAVR), and to provide standardized recommendations for the development of emergency TAVR technology in China.Methods:This study retrospectively analyzed the relevant data of patients undergoing emergency TAVR surgery in the Second Affiliated Hospital of Zhejiang University School of Medicine from March 2019 to February 2021, including baseline patient characteristics, perioperative echocardiography data, prognosis and 30-day follow-up. Post-operative data were compared with pre-operative data using paired-sample test.Results:Thirteen patients, aged (75.62±9.63) years, underwent emergency TAVR surgery, and 6 of them were male. Eleven patients were New York Heart Association class Ⅳ. The preoperative Society of Thoracic Surgeons score was (20.31±15.15)%. The trans-aortic valve differential pressure was significantly reduced after surgery [(68.92±30.66)mmHg vs. (2.70±2.36)mmHg, P<0.01]. Two patients died within 30 days after surgery, one patient developed a new third degree atrioventricular block, one patient had a stroke, and 4 patients developed pulmonary infection. Conclusions:Emergency TAVR surgery is a feasible and effective rescue strategy for patients with aortic stenosis in critical condition. The establishment of anesthesia standard operation procedure process for TAVR surgery helps ensure homogenized medical behavior and good teamwork.
-
The role of the vascular surgeon in transcatheter aortic valve implantation
Enrico Gallitto,Gianluca Faggioli,Francesco Saia,Tullio Palmerini,Rodolfo Pini,Antonio Giulio Bruno,Francesca Maria Feroldi,Moad Alaidros,Gabriele Ghetti,Nevio Taglieri,Stefania Caputo,Francesco Donati,Cinzia Marrozzini,Mauro Gargiulo
DOI: https://doi.org/10.1177/17085381241237844
IF: 1.1
2024-03-20
Vascular
Abstract:Vascular, Ahead of Print. BackgroundTranscatheter aortic valve implantation (TAVI) has become the standard treatment for severe aortic valve stenosis in patients at increased surgical risk. Percutaneous transfemoral (TF) is the access of choice due to its reduced invasiveness and perioperative morbidity/mortality compared with the trans-axillary, aortic, and apical routes. On the other hand, vascular access complications (VACs) of the TF access are associated with prolonged hospitalization, 30-day, and 1-year mortality. In addition, the concomitance of peripheral arterial disease may require associated endovascular management. A multidisciplinary team with Interventional Cardiologists and Vascular Surgeons may minimize the rate of VACs in patients with challenging femoral-iliac access or concomitant disease of other vascular districts, thus optimizing the outcome of TF-TAVI. The aim of this study was to evaluate the role of Vascular Surgeons in TF TAVI procedures.MethodsWe conducted a retrospective single-center review of all TF-TAVI procedures assisted by Vascular Surgeons between January 2016 and December 2020 in a high-volume tertiary hospital. Pre, intra, and postoperative data were analyzed by a dedicated group of Interventional Cardiologists and Vascular Surgeons. VACs were defined according with the Valve Academic Research Consortium (VARC) three guidelines. The outcomes of TF-TAVI procedures with Vascular Surgeons involvement were assessed as study's endpoints.ResultsOverall, 937 TAVI procedures were performed with a TF approach ranging between 78% (2016) and 98% (2020). Vascular Surgeons were involved in 67 (7%) procedures with the following indications: concomitant abdominal aortic aneurysm (EVAR + TAVI) - 3 (4%), carotid stenosis (TAVI + CAS) - 2 (3%), hostile femoral/iliac access, or VACs - 62 (93%). Balloon angioplasty of iliac artery pre-TAVI implantation was performed in 51 cases (conventional PTA: 38/51%–75%; conventional PTA + intravascular lithotripsy: 13/51%–25%; stenting: 5/51%–10%). TAVI procedure was successfully completed by percutaneous TF approach in all 62 cases with challenging femoral/iliac access. VACs necessitating interventions were 18/937 (2%) cases, localized to the common femoral or common/external iliac artery in 15/18 (83%) and 3/18 (17%) cases, respectively. They were managed by surgical or endovascular maneuvers in 3/18 (17%) and 15/18 (83%) cases, respectively. Fifteen/18 (83%) VACs were treated during the index procedure. There was no procedure-related mortality or 30-day readmission.ConclusionIn our experience, Vascular Surgeon assistance in TAVI procedures was not infrequent and allowed safe and effective device introduction through challenging TF access. Similarly, the concomitant significant disease of other vascular districts could be safely addressed, potentially reducing postoperative related mortality and morbidity. The implementation of multidisciplinary team with interventional cardiologists and vascular surgeons should be encouraged whenever possible.
peripheral vascular disease
-
Transcatheter Aortic Valve Replacement (TAVR): Access Planning and Strategies
Basel Ramlawi,Javier E. Anaya-Ayala,Michael J. Reardon
DOI: https://doi.org/10.14797/mdcj-8-2-22
2012-04-01
Methodist DeBakey Cardiovascular Journal
Abstract:Transcatheter aortic valve replacement (TAVR) has proven to be a viable tool for the high-surgical-risk population with severe aortic valve stenosis. Vascular access complications are not uncommon with TAVR and may increase early and late mortality. Avoiding these serious complications is the goal. With experience and careful screening, we are now able to risk-stratify patients who may be at increased risk of vascular complications. While the traditional iliofemoral access site remains the most common for TAVR, alternate access sites that have proven to be viable and safe alternatives include the transapical, direct-aortic, and subclavian techniques. TAVR teams should be familiar and comfortable with these approaches as each of them has its own advantages and weaknesses. The best option is usually one in which the procedure is tailored to the patient. The present review examines our current access planning and strategies for TAVR.
English Else
-
Emergently Alteration of Procedural Strategy During Transcatheter Aortic Valve Replacement to Prevent Coronary Occlusion: A Case Report
Hanyi Dai,Dao Zhou,Jiaqi Fan,Lihan Wang,Abuduwufuer Yidilisi,Gangjie Zhu,Jubo Jiang,Huajun Li,Xianbao Liu,Jian'an Wang
DOI: https://doi.org/10.3389/fcvm.2022.931595
IF: 3.6
2022-01-01
Frontiers in Cardiovascular Medicine
Abstract:BackgroundCoronary occlusion is an uncommon but fatal complication of transcatheter aortic valve replacement (TAVR) with a poor prognosis. Case PresentationA patient with symptomatic severe bicuspid aortic valve stenosis was admitted to a high-volume center specializing in transfemoral TAVR with self-expanding valves. No anatomical risk factors of coronary occlusion were identified on pre-procedural computed tomography analysis. The patient was scheduled for a transfemoral TAVR with a self-expanding valve. Balloon pre-dilatation prior to prosthesis implantation was routinely used for assessing the supra-annular structure and assessing the risk of coronary occlusion. Immediately after the tubular balloon inflation, fluoroscopy revealed that the right coronary artery was not visible, and the flow in the left coronary artery was reduced. The patient would be at high-risk of coronary occlusion if a long stent self-expanding valve was implanted. Therefore, our heart team decided to suspend the ongoing procedure. A transapical TAVR with a 23 mm J-valve was performed 3 days later. The prosthesis was deployed at a proper position without blocking the coronary ostia and the final fluoroscopy showed normal flow in bilateral coronary arteries with the same filling as preoperatively. DiscussionOur successful case highlights the importance of a comprehensive assessment of coronary risk and a thorough understanding of the TAVR procedure for the heart team. A short-stent prosthesis is feasible for patients at high risk of coronary occlusion. Most importantly TAVR should be called off even if the catheter has been introduced when an extremely high risk of coronary obstruction is identified during the procedure and no solution can be found.
-
Transapical aortic valve implantation using J-Valve? system for high-risk patients with aortic regurgitation: mid-stage of 1 year follow-up
洪泽,孔敏坚,刘先宝,朱贤,王建安,董爱强
DOI: https://doi.org/10.3760/cma.j.cn112434-20210806-00256
2022-01-01
Abstract:Objective:To analysis the mid-stage prognosis of transapical aortic valve implantation(TA-TAVI) using J-Valve? system for the treatment of high-risk aortic regurgitation(AR) patients.Methods:Data of 25 patients with aortic regurgitation who had underwent transapical aortic valve implantation using J-Valve? system were collected in the Second Affiliated Hospital of Medical College of ZheJiang University from September 2016 to June 2020 . Analysis and summarize their postoperative all-cause mortality, the incidence of adverse events and the improvement in cardiac function.Results:There were 25 patients, including 19 males, the age rage from 59-83 years, the average age was(72.3±27.11) years. The levels of aortic regurgitation was evaluated by transthoracic echocardiography preoperatively, showed that severe AR accounted for 88%. The New York Heart Association(NYHA) of grade 3 or above was 92%. The most common comorbidity was hypertension, accounted for 68%. Coronary heart disease and history of cardiac surgery was 5 and 3 relatively in this study. The Society of Thoracic Surgeons score before surgery was 1.511%-27.674%, the average of STS score was 4.27(2.914-6.033)%. Successful J-Valve implantation was obtained in all 25 cases, no conversion to thoracotomy. After surgery, 2 patients required permanent pacemaker implantation, 1 patient needed continuous renal replacement therapy(CRRT) due to acute kidney injury, 1 occurred moderate or above paravalvular leak. The results showed good therapeutic effects in early-stage, low incidences of adverse events. The continued improvement of cardiac function and ventricular reverse remodeling could be observed in mid-stage.Conclusion:In this study, we can summarize that high-risk patients with aortic regurgitation treated with transapical aortic valve implantation using J-Valve? system can acquire great perioperative safety and mid-stage prognosis.
-
[Value of Preoperative Assessment on Transcatheter Aortic Valve Implantation Procedure with High-Pitch Dual-Source Computed Tomography Angiography].
Qijing Zhou,Xianbao Liu,Aiqiang Dong,Zhaoxia Pu,Wei He,Yan Feng,Jian'an Wang
DOI: https://doi.org/10.3760/cma.j.issn.0253-3758.2014.10.009
2014-01-01
Abstract:OBJECTIVE:To evaluate the value of preoperative assessment on transcatheter aortic valve implantation (TAVI) procedure with high-pitch dual-source computed tomography angiography (CTA).METHODS:Seventeen consecutive patients with severe symptomatic aortic stenosis underwent TAVI in our department from December 2012 to December 2013 were examined by 128-slice prospective ECG-triggered high-pitch spiral CTA and the clinical data were analyzed. Aortic annulus, sinus of Valsalva, sinotubular junction, ascending aorta and native leaflet to coronary ostium length were measured. Peripheral vascular access was evaluated. Then the patients were assessed on the suitability for TAVI procedure and prosthetic valve sizes.RESULTS:Mean diameter of the aortic annulus was (25.7 ± 2.0) mm, perimeter mean diameter was (26.4 ± 2.0) mm, area mean diameter was (25.4 ± 1.9) mm. Mean diameter of sinus of Valsalva was (34.0 ± 3.8) mm. Mean diameter of sinotubular junction was (30.5 ± 3.2) mm. Mean diameter of ascending aorta was (37.8 ± 2.8) mm. The length from native leaflet to left coronary ostium was (14.0 ± 2.0) mm, and the length from native leaflet to right coronary ostium was (15.9 ± 3.6) mm. Mean diameter of left iliac arteries was (7.5 ± 1.4) mm. Mean diameter of right iliac arteries was (7.4 ± 1.2) mm. Mean diameter of left femoral arteries was (7.4 ± 1.2) mm. Mean diameter of right femoral arteries was (7.3 ± 1.3) mm. One patient was considered ineligible for TAVI because of large aortic annulus diameter. Three patients died prior to TAVI. Two patients refused to undergo TAVI. Eleven patients underwent TAVI, 26# prosthetic valve was implanted in 1 patient, 29# prosthetic valve implanted in 6 patients, 31# prosthetic valve implanted in 4 patients. Prosthetic valve implantation was successful in 9 patients and only mild or trace perivalvular leakage was observed in these patients. Moderate perivalvular leakage were observed in 2 patients because of the location of implantation was too low, and perivalvular leakage was significantly reduced after re-implantation with same size prosthetic valve at a higher location.CONCLUSIONS:CTA can be used to evaluate the aortic root anatomy and vascular access, and help to choose the right size of prosthetic valve. CTA has an important practical value in preoperative screening of TAVI procedure.
-
Interpretation of 2015 Experts Consensus for Transcatheter Aortic Valve Replacement
Yaling HAN,Kai XU,Mao CHEN
DOI: https://doi.org/10.7507/1002-0179.201801153
2018-01-01
Abstract:Transcatheter aortic valve replacement (TAVR) developed rapidly since firstly introduced to clinical practice in 2002.In 2015,Experts Consensus for Transeatheter Aortic Valve Replacement (abbreviated as the Consensus)helped TAVR develop normatively and safely in China.This article interpreted the Consensus in combination of new evolutions of TAVR field:first,the indications of TAVR expand from inoperative and high risk patients to the intermediate risk patients;second,although the Consensus recommended pre-dilation with balloon of modest size,the necessity of pre-dilation is under debate;third,the Consensus pointed out main complications of TAVR,and the main strategies to avoid complications are careful pre-procedural analysis and development of new device;fourth,our experts had made outstanding contribution to TAVR in the treatment of patients with bicuspid aortic valve,which still has many problems to be solved urgently.
-
A Coronary-Friendly Device Mitigating Risk of Coronary Obstruction in Transcatheter Aortic Valve Replacement
Yuntao Lu,Minyan Yin,Ye Yang,Wenshuo Wang,Lili Dong,Xue Yang,Chunsheng Wang,Xiaolin Wang,Jinmiao Chen,Lai Wei
DOI: https://doi.org/10.2147/cia.s467594
IF: 3.829
2024-09-26
Clinical Interventions in Aging
Abstract:Yuntao Lu, 1, 2, &ast Minyan Yin, 3, 4, &ast Ye Yang, 1, 2, &ast Wenshuo Wang, 1, 2 Lili Dong, 5 Xue Yang, 3, 4 Chunsheng Wang, 1, 2 Xiaolin Wang, 3, 4 Jinmiao Chen, 1, 2 Lai Wei 1, 2 1 Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Shanghai Engineering Research Center of Heart Valve, Shanghai, People's Republic of China; 3 Shanghai Institute of Medical Imaging, Shanghai, People's Republic of China; 4 Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 5 Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lai Wei; Jinmiao Chen, Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Tel +86 021 64041990, Email ; Purpose: Transcatheter aortic valve replacement (TAVR) induced coronary artery obstruction (CAO) is a rare but devastating complication. Current preventive strategies need additional procedures and may be associated with adverse events. This study aimed to evaluate the early safety and efficacy of stand-alone TAVR using the J-Valve (Jianshi JieCheng Medical Technology Co. Ltd, Shanghai, China) in patients at potential high risk for CAO. Patients and Methods: CAO was defined as coronary ostia obstruction requiring intervention. Patients at potential high risk for CAO were identified retrospectively from 673 consecutive patients who underwent TAVR from January 2015 to July 2021 at Zhongshan Hospital, Fudan University. Procedural results and early outcomes were evaluated according to Valve Academic Research Consortium-3 definitions. Results: A total of 20 consecutive patients (age 72 ± 9 years; 85% female;) were included. The Society of Thoracic Surgeons-Predicted Risk of Mortality was 5% (interquartile range, 4 to 10%). All patients (100%) had at least 2 classical risk factors for CAO by pre-procedural computed tomography analysis, and 90% patients had native aortic valve diseases. TAVR was successful in 95% of cases, with only 1 patient requiring second device implantation. Early safety at 30 days was achieved in all cases without death. All patients were free from CAO, stroke or emergency reintervention. Post-procedural mean aortic valve gradient was 7 (interquartile range, 4, 12) mmHg, and none/trace or mild aortic regurgitation was present in all patients. Conclusion: Stand-alone TAVR using the J-Valve may mitigate the risk of TAVR-induced CAO. Keywords: TAVR, coronary artery obstruction, aortic regurgitation, aortic stenosis, structural heart disease Graphical Coronary artery obstruction (CAO) in transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve implantation (TAVIV) is caused by the displacement of the diseased leaflet (native valve or bioprostheses) toward the coronary ostia and/or sinotubular junction (STJ) by the implanted transcatheter heart valve (THV). It is a rare complication (incidence < 1% in TAVR, ≈3% in TAVIV); however, it is likely to be underestimated, as many patients are excluded from TAVR due to potential CAO risk. 1–3 TAVR-induced CAO is devastating because the 30-day mortality rate is 52.9%. 3 Risk factors for CAO during TAVR include but not limited to female, low-lying coronary ostia, narrow sinus of Valsalva, bioprostheses with externally mounted leaflets and stentless surgical valve. 1,3 Surgical aortic valve replacement is the standard treatment for patients at high risk of TAVR-induced CAO. Additional interventions may be useful, including coronary protection with pre-emptive wiring and stenting (regular stent and chimney technique) 4,5 and bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA). 6,7 Although both techniques have the potential to prevent CAO in selected patients, they are also associated with the risk of serious complications, such as stent failure and stroke. 8 J-Valve (Jianshi JieCheng Medical Technology Co, Ltd, Shanghai, China) is a self-expanding, low-profile transapical heart valve. Previous studies have reported the feasibility of the J-Valve for treatment in aortic regurgitation and/or stenosis, and the mid-term outcomes were promising. 9–11 J-Valve was reported to use as a new opti -Abstract Truncated-
geriatrics & gerontology,gerontology
-
Transcatheter aortic valve replacement: Past, present, and future
Akash Srinivasan,Felyx Wong,Brian Wang
DOI: https://doi.org/10.1002/clc.24209
2024-01-16
Clinical Cardiology
Abstract:In this review, we provide an updated overview of the TAVR procedure, the main aspects of preprocedural patient assessment, and the key complications of the procedure. We also summarize the current evidence comparing TAVR and SAVR, before exploring the potential future directions for TAVR. Created with BioRender. Transcatheter aortic valve replacement (TAVR) has emerged as a ground‐breaking, minimally invasive alternative to traditional open‐heart surgery, primarily designed for elderly patients initially considered unsuitable for surgical intervention due to severe aortic stenosis. As a result of successful large‐scale trials, TAVR is now being routinely applied to a broader spectrum of patients. In deciding between TAVR and surgical aortic valve replacement, clinicians evaluate various factors, including patient suitability and anatomy through preprocedural imaging, which guides prosthetic valve sizing and access site selection. Patient surgical risk is a pivotal consideration, with a multidisciplinary team making the ultimate decision in the patient's best interest. Periprocedural imaging aids real‐time visualization but is influenced by anaesthesia choices. A comprehensive postprocedural assessment is critical due to potential TAVR‐related complications. Numerous trials have demonstrated that TAVR matches or surpasses surgery for patients with diverse surgical risk profiles, ranging from extreme to low risk. However, long‐term follow‐up data, particularly in low‐risk cases, remains limited, and the applicability of published results to younger patients is uncertain. This review delves into key TAVR studies, pinpointing areas for potential improvement while delving into the future of this innovative procedure. Furthermore, it explores the expanding role of TAVR technology in addressing other heart valve replacement procedures.
cardiac & cardiovascular systems
-
Challenges and future opportunities for transcatheter aortic valve therapy
Martin B Leon,Hemal Gada,Gregory P Fontana
DOI: https://doi.org/10.1016/j.pcad.2014.03.004
Abstract:Background: Transcatheter aortic valve replacement (TAVR) is a novel less-invasive therapy for high-risk patients with severe aortic stenosis (AS). Despite the impressive clinical growth of TAVR, there are many challenges as well as future opportunities. Results: The heart valve team serves as the central vehicle for determining appropriate case selection. Considerations which impact clinical therapy decisions include frailty assessments and defining clinical "futility". There are many controversial procedural issues; choice of vascular access site, valve sizing, adjunctive imaging, and post-dilatation strategies. Complications associated with TAVR (strokes, vascular and bleeding events, para-valvular regurgitation, and conduction abnormalities) must be improved and will require procedural and/or technology enhancements. TAVR site training mandates a rigorous commitment to established society and sponsor guidelines. In the future, TAVR clinical indications should extend to bioprosthetic valve failure, intermediate risk patients, and other clinical scenarios, based upon well conducted clinical trials. New TAVR systems have been developed which should further optimize clinical outcomes, by reducing device profile, providing retrievable features, and preventing para-valvular regurgitation. Other accessory devices, such as cerebral protection to prevent strokes, are also being developed and evaluated in clinical studies. Summary: TAVR is a worthwhile addition to the armamentarium of therapies for patients with AS. Current limitations are important to recognize and future opportunities to improve clinical outcomes are being explored.
-
An Updated Comprehensive Review of Existing Transcatheter Aortic Valve Replacement Access
Wenjing Sheng,Hanyi Dai,Rongrong Zheng,Ailifeire Aihemaiti,Xianbao Liu
DOI: https://doi.org/10.1007/s12265-024-10484-z
Abstract:For the past 20 years, transcatheter aortic valve replacement (TAVR) has been the treatment of choice for symptomatic aortic stenosis. The transfemoral (TF) access is considered the gold standard approach for TAVR. However, TF-TAVR cannot be performed in some patients; thus, alternative accesses are required. Our review paper generalises the TAVR accesses currently available, including the transapical, transaortic, trans-subclavian/axillary, transcarotid, transcaval, and suprasternal approaches. Their advantages and disadvantages have been analysed. Since there is no standard recommendation for an alternative approach, access selection depends on the expertise of the local cardiac team, patient characteristics, and access properties. Each TAVR centre is recommended to master a minimum of one non-TF access alternative. Of note, more evidence is required to delve into the clinical outcomes of each approach, at both early and long-term (Figure 1).
-
Cardiac computed tomography post-transcatheter aortic valve replacement
Albert He,Ben Wilkins,Nick S R Lan,Farrah Othman,Amro Sehly,Vikas Bhat,Biyanka Jaltotage,Girish Dwivedi,Jonathon Leipsic,Abdul Rahman Ihdayhid
DOI: https://doi.org/10.1016/j.jcct.2024.04.014
Abstract:Transcatheter aortic valve replacement (TAVR) is performed to treat aortic stenosis and is increasingly being utilised in the low-to-intermediate-risk population. Currently, attention has shifted towards long-term outcomes, complications and lifelong maintenance of the bioprosthesis. Some patients with TAVR in-situ may develop significant coronary artery disease over time requiring invasive coronary angiography, which may be problematic with the TAVR bioprosthesis in close proximity to the coronary ostia. In addition, younger patients may require a second transcatheter heart valve (THV) to 'replace' their in-situ THV because of gradual structural valve degeneration. Implantation of a second THV carries a risk of coronary obstruction, thereby requiring comprehensive pre-procedural planning. Unlike in the pre-TAVR period, cardiac CT angiography in the post-TAVR period is not well established. However, post-TAVR cardiac CT is being increasingly utilised to evaluate mechanisms for structural valve degeneration and complications, including leaflet thrombosis. Post-TAVR CT is also expected to have a significant role in risk-stratifying and planning future invasive procedures including coronary angiography and valve-in-valve interventions. Overall, there is emerging evidence for post-TAVR CT to be eventually incorporated into long-term TAVR monitoring and lifelong planning.
-
Complications in transcatheter aortic valve replacement: A comprehensive analysis and management strategies
Qi Zou,Zhiliang Wei,Shougang Sun
DOI: https://doi.org/10.1016/j.cpcardiol.2024.102478
IF: 16.464
2024-05-01
Current Problems in Cardiology
Abstract:Transcatheter Aortic Valve Replacement (TAVR) marks a significant advancement in treating aortic stenosis (AS), especially for patients with high surgical risks. This concise review outlines TAVR's development, its broader application to include lower-risk patients, and innovations in the device and procedural technology. Clinical trials, notably the PARTNER series, affirm TAVR's efficacy, showing it matches or surpasses surgical aortic valve replacement (SAVR) in mortality reduction, hemodynamic benefits, and symptom alleviation, including heart failure. However, TAVR entails complications such as paravalvular leakage (PVL), conduction disorders, and increased cerebrovascular event risks. We evaluate these issues, their prevalence, causative factors, and clinical consequences, emphasizing improvements in valve design and technique that have significantly lowered PVL rates. The role of aortic valve anatomy and calcification in PVL and conduction issues is analyzed, underlining the necessity for meticulous patient selection and procedural planning. Further, the review delves into cerebrovascular event risks, their origins, and preventative strategies, including cerebral protection devices and the judicious use of anticoagulant and antiplatelet therapies. TAVR presents a less invasive, promising alternative to SAVR, but requires careful complication management to optimize patient results. Ongoing innovation and research are vital for advancing TAVR's techniques, improving valve designs, and extending its reach, thereby enhancing AS patients' quality of life.
cardiac & cardiovascular systems
-
A Guide to Transcatheter Aortic Valve Design and Systematic Planning for a Redo-TAV (TAV-in-TAV) Procedure
Vinayak N Bapat,Miho Fukui,Syed Zaid,Atsushi Okada,Hasan Jilaihawi,Toby Rogers,Omar Khalique,João L Cavalcante,Uri Landes,Janarthanan Sathananthan,Giuseppe Tarantini,Gilbert H L Tang,Daniel J Blackman,Ole De Backer,Michael J Mack,Martin B Leon
DOI: https://doi.org/10.1016/j.jcin.2024.04.047
2024-07-22
Abstract:Transcatheter aortic valve replacement (TAVR) has become more common than surgical aortic valve replacement since 2016, with over 200,000 procedures globally each year. As patients increasingly outlive their TAVR devices, managing these cases is a growing concern. Treatment options include surgical removal of the old TAVR device (transcatheter aortic valve [TAV] explant) or implantation of a new transcatheter aortic valve (redo TAV). Redo TAV is complex because of the unique designs of TAV devices; compatibility issues; and the need for individualized planning based on factors such as implant depth, shape, and coronary artery relationships. This review serves as a comprehensive guide for redo TAV, detailing the design characteristics of TAV devices, device compatibility, standardized terminology, and a structured approach for computed tomography analysis. It aims to facilitate decision making, risk identification, and achieving optimal outcomes in redo TAV procedures.
-
Impact of cardiac rehabilitation on pre- and post-operative transcatheter aortic valve replacement prognoses
Jieru Zou,Jie Yuan,Jingjin Liu,Qingshan Geng
DOI: https://doi.org/10.3389/fcvm.2023.1164104
2023-12-13
Abstract:Transcatheter aortic valve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels. Indeed, among high-risk patients, TAVR outcomes are comparable to, or even better, than that of the traditional surgical aortic valve replacement (SAVR) method. TAVR outcomes, with respect to post-surgical functional capacity and quality of life, have also been found to be improved, especially when combined with cardiac rehabilitation (CR). CR is a multidisciplinary system, which integrates cardiology with other medical disciplines, such as sports, nutritional, mind-body, and behavioral medicine. It entails the development of appropriate medication, exercise, and diet prescriptions, along with providing psychological support, ensuring the cessation of smoking, and developing risk factor management strategies for cardiovascular disease patients. However, even with CR being able to improve TAVR outcomes and reduce post-surgical mortality rates, it still has largely been underutilized in clinical settings. This article reviews the usage of CR during both pre-and postoperative periods for valvular diseases, and the factors involved in influencing subsequent patient prognoses, thereby providing a direction for subsequent research and clinical applications.
-
Chinese expert consensus on transfemoral transcatheter aortic valve replacement for pure aortic regurgitation (2023)
DOI: https://doi.org/10.1097/cp9.0000000000000090
2024-08-01
Cardiology Plus
Abstract:Transcatheter aortic valve replacement (TAVR) was initially used to treat aortic stenosis (AS), and gradually expanded into aortic regurgitation (AR) treatment. Scholars worldwide have explored the use of marketed transfemoral TAVR (TF-TAVR) valves for AR patients, offering another option for high-risk surgical patients. However, AR presents distinct challenges compared to AS, including anatomical differences, valve selection, procedural nuances, and complication profiles. Overall, TF-TAVR for AR is more complex with lower success rate than for AS. In order to promote the safe and standardized TF-TAVR for AR in China, the Structural Heart Disease Group of Chinese College of Cardiovascular Physician drafted this consensus. The writing expert team focused on key clinical challenges in TF-TAVR for AR patients, combining evidence from literature up to September 1, 2023, to formulate nine core viewpoints. These encompass indications, valve selection, preoperative evaluation, intraoperative techniques, complication prevention and management, postoperative care, and other aspects.